Cardiology Today's Intervention top stories covered at TCT 2017

TCT 2017 featured important late-breaking clinical trials and other presentations by some of the world’s leading interventional cardiologists. Cardiology Today’s Intervention has compiled a list of the top studies, presentations and abstracts presented at the meeting this year.

Highlights from this year’s meeting include the CULPRIT-SHOCK trial, the ORBITA trial, the SENIOR trial, Intrepid Pilot study, a cost-effectiveness and quality-of-life analysis of balloon-expandable transcatheter aortic valve replacement systems and much more.

CULPRIT-SHOCK: Culprit lesion only may be superior to immediate multivessel PCI

The 30-day risk for composite death or severe renal failure leading to renal-replacement therapy in patients with multivessel CAD and acute MI with cardiogenic shock was lower among those who underwent PCI of the culprit lesion only compared with those who received immediate multivessel PCI, according to the results of the CULPRIT-SHOCK trial, presented at TCT 2017.

ORBITA puts spotlight on PCI vs. sham procedure

Exercise time was not significantly increased among patients with medically treated angina and severe coronary stenosis who underwent PCI compared with a sham procedure, according to the results of the ORBITA trial, presented at TCT 2017.

The controversial trial, simultaneously published in The Lancet, was conducted to determine the background symptomatic relief of PCI among patients with stable angina in a placebo-controlled randomized trial.

SENIOR: PCI with DES, short DAPT confers improved outcomes in older patients

Older patients who underwent PCI with a bioabsorbable polymer drug-eluting stent and a short duration of dual antiplatelet therapy had fewer instances of MI, all-cause mortality, ischemia-driven target lesion revascularization and stroke compared with those with a bare-metal stent, according to data presented at TCT 2017.

“The SENIOR trial gives you the opportunity in these patients to reduce the duration of DAPT while you’re still offering a benefit of a lower revascularization rate with the latest-generation drug-eluting stent,” Olivier Varenne, MD, PhD, of Hôpital Cochin in Paris and the cardiology department at Université Paris Descartes, said during a press conference.

Intrepid Pilot: Transcatheter mitral valve replacement may be safe alternative to surgery

The use of a transcatheter mitral valve replacement system appears to be safe and effective in the treatment of patients with mitral regurgitation who were considered ineligible for conventional valve surgery, according to the results of the Intrepid Pilot study, presented at TCT 2017.

PARTNER 2A, S3i: TAVR reduces cost, improves life expectancy in severe aortic stenosis

Patients with severe aortic stenosis and intermediate surgical risk who underwent TAVR with two different valves had lower long-term costs and a greater quality-adjusted life expectancy compared with those who underwent surgical AVR, according to data from two trials presented at TCT 2017.